Alliance Pharmaceutical Corp. (NASDAQ:ALLP) of San Diegoannounced that it has resumed the Phase I U.S. human clinicaltrial for its Oxygent HT product, a perflubron-based emulsionfor use as a temporary oxygen carrier (red blood cellsubstitute) during elective surgeries. The trial was interruptedabout a year ago as a result of a raw material manufacturingproblem, which has been corrected. The trial was also delayedlast fall because the company decided to perform additionalnon-clinical safety studies.
(c) 1997 American Health Consultants. All rights reserved.